ARS Pharmaceuticals, Inc. (SPRY)
(Real Time Quote from BATS)
$13.28 USD
+0.28 (2.15%)
Updated Aug 15, 2024 01:34 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
ARS Pharmaceuticals, Inc. (SPRY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.00 | $22.00 | $20.00 | 61.54% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for ARS Pharmaceuticals, Inc. comes to $21.00. The forecasts range from a low of $20.00 to a high of $22.00. The average price target represents an increase of 61.54% from the last closing price of $13.00.
Analyst Price Targets (2 )
Broker Rating
ARS Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 2 | 2 | 2 | 3 |
Buy | 0 | 1 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.33 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Raymond James | Ryan Deschner | Strong Buy | Strong Buy |
8/9/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
8/9/2024 | SVB Securities | Roanna Ruiz | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 3 |
Average Target Price | $21.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -0.18 |